Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifaximin for Cirrhotic Gastroesophageal Variceal Hemorrhage
NCT02964195Unknown
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Nov 2016
- Primary completion
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of rifaximin in Gastroesophageal Variceal Hemorrhage (2 arms), sponsored by Zhongshan Hospital, Fudan University. Primary endpoint: All clinical events at 8 weeks. Status: unknown.
02
Drugs
rifaximin
03
Conditions
Gastroesophageal Variceal Hemorrhage
Beyond the preview
Go deeper on NCT02964195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02964195.